Latest news
Final ASTRUM-002 Analysis Shows Survival Benefit with Hetronifly in Advanced nsqNSCLC After Four Years of Follow-Up - EIN PresswireEIN Presswire · Mon, 10 Aug 2026 00:00:00 GMTShanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value? - simplywall.stsimplywall.st · Sun, 09 Aug 2026 23:31:05 GMTEnterprise value to EBITDA forward of Shanghai Henlius Biotech, Inc. Class H – DUS:2E8 - TradingViewTradingView · Sat, 08 Aug 2026 15:13:30 GMTShanghai Henlius Biotech, Inc. Announces Approval of Investigational New Drug Application for Clinical Trial of HLX43 for Injection in Combination with Bevacizumab for Treatment of Advanced or Metastatic Solid Tumours - marketscreener.commarketscreener.com · Fri, 31 Jul 2026 08:31:00 GMT